Literature DB >> 11704685

Index case of fatal inhalational anthrax due to bioterrorism in the United States.

L M Bush1, B H Abrams, A Beall, C C Johnson.   

Abstract

Entities:  

Mesh:

Year:  2001        PMID: 11704685     DOI: 10.1056/NEJMoa012948

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  55 in total

1.  Inhalational anthrax: radiologic and pathologic findings in two cases.

Authors:  Bradford J Wood; Bryan DeFranco; Mary Ripple; Martin Topiel; Carlos Chiriboga; Venkat Mani; Kevin Barry; Dave Fowler; Henry Masur; Luciana Borio
Journal:  AJR Am J Roentgenol       Date:  2003-10       Impact factor: 3.959

Review 2.  Respiratory medical societies and the threat of bioterrorism.

Authors:  T G O'Riordan; G C Smaldone
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

3.  The primary care differential diagnosis of inhalational anthrax.

Authors:  Jonathan L Temte; Andrew R Zinkel
Journal:  Ann Fam Med       Date:  2004 Sep-Oct       Impact factor: 5.166

4.  Clinician use and acceptance of population-based data about respiratory pathogens: implications for enhancing population-based clinical practice.

Authors:  Per H Gesteland; Mandy A Allison; Catherine J Staes; Matthew H Samore; Michael A Rubin; Marjorie E Carter; Amyanne Wuthrich; Anita Y Kinney; Susan Mottice; Carrie L Byington
Journal:  AMIA Annu Symp Proc       Date:  2008-11-06

5.  Real-time public health surveillance for emergency preparedness.

Authors:  Jean-Paul Chretien; Nancy E Tomich; Joel C Gaydos; Patrick W Kelley
Journal:  Am J Public Health       Date:  2009-06-18       Impact factor: 9.308

6.  Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Authors:  Deborah J Stearns-Kurosawa; Florea Lupu; Fletcher B Taylor; Gary Kinasewitz; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

7.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

8.  Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay.

Authors:  R E Biagini; D L Sammons; J P Smith; E H Page; J E Snawder; C A F Striley; B A MacKenzie
Journal:  Occup Environ Med       Date:  2004-08       Impact factor: 4.402

9.  Call-tracking data and the public health response to bioterrorism-related anthrax.

Authors:  Joshua A Mott; Tracee A Treadwell; Thomas W Hennessy; Paula A Rosenberg; Mitchell I Wolfe; Clive M Brown; Jay C Butler
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

10.  Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response.

Authors:  Vincent P Hsu; Susan L Lukacs; Thomas Handzel; James Hayslett; Scott Harper; Thomas Hales; Vera A Semenova; Sandra Romero-Steiner; Cheryl Elie; Conrad P Quinn; Rima Khabbaz; Ali S Khan; Gregory Martin; John Eisold; Anne Schuchat; Rana A Hajjeh
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.